Olema Pharma Q3 net loss widens on higher costs

Olema Oncology

10/11/2026 12:11

Overview
US biopharma firm's Q3 net loss widened from a year earlier
Higher R&D and clinical trial costs drove increased quarterly loss
Company ended Q3 with $413.8 mln in cash and equivalents

Outlook
Company expects top-line data from Phase 3 OPERA-01 trial in Q1 2027
Strong enrollment continues in Phase 3 OPERA-02 and Phase 1b/2 OP-3136 trials
Company plans to start Phase 1b/2 OP-3136 and darolutamide study in Q4 2026

Result Drivers
CLINICAL TRIAL ENROLLMENT - Co said higher net loss was mainly due to increased enrollment in OPERA-01 and OPERA-02 Phase 3 trials and advancement of OP-3136 program
R&D AND MANUFACTURING COSTS - Co cited higher R&D and manufacturing costs, as well as increased personnel expenses, as drivers of higher operating expenses
G&A EXPENSES - Higher G&A expenses driven by increased investment in personnel, corporate infrastructure, and commercialization preparations

Company press release: ID:nGNX8nM0S7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Loss
 
$73.60 mln
 
Q3 Income From Operations
 
-$77.53 mln
 
Q3 Operating Expenses
 
$77.53 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Olema Pharmaceuticals, Inc. is $36.00, about 389.1% above its November 9 closing price of $7.36

Reuters Recommended Reads
Nov 9 - Structure Therapeutics Q3 loss widens on higher R&D costs
Nov 9 - Rani Therapeutics Q3 net loss widens on higher R&D costs
Nov 9 - Trevi Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)